Fatty Liver in Pregnancy

Prospective Observational Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00471575

Enrollment

Unknown

Registered

2007-05-10

Start date

2007-06-30

Completion date

2007-12-31

Last updated

2007-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver

Keywords

fatty liver, pregnancy, ultra sound, Pregnant women at the end of pregnancy or immediately after birth., controls-women with normal liver, correlation between ultrasonography and nutritional, obsthetric and laboratory data.

Brief summary

Non alcoholic fatty liver disease (NAFLD) is one of the main causes of development of chronic liver disease and cirrhosis. There are no published studies which have investigated the incidence of NAFLD in pregnant women or the correlation between the metabolic changes in pregnancy and this phenomenon. We aimed in our study to explore the incidence of NAFLD in pregnancy by ultrasonography (US) during the end of the pregnancy or immediately after birth (after 36 weeks) and to look for a correlation between fatty liver and demographic, clinical, nutritional and laboratory data during pregnancy.

Detailed description

Fatty liver in pregnancy-protocol: Non alcoholic fatty liver disease (NAFLD) is one of the main causes of development of chronic liver disease and cirrhosis. The incidence of NAFLD among the general population is about 17-30%. There are no published studies which have investigated the incidence of NAFLD in pregnant women or the correlation between the metabolic changes in pregnancy and this phenomenon. We aimed in our study to explore the incidence of NAFLD in pregnancy by ultrasonography (US) during the end of the pregnancy or immediately after birth (after 36 weeks) and to look for a correlation between fatty liver and demographic, clinical, nutritional and laboratory data during pregnancy. Methods: US examination will be performed by an experienced technician. The liver will be scanned by B mode US using a 2-5 MHZ transducer. In those with fatty liver as seen by US, a repeat examination will be performed after 6 weeks and 24 weeks. For women with the diagnosis of fatty liver, serum lipid profile, glucose, liver function tests and insulin will be done. Homa score as well as BMI will be calculated for each woman with fatty liver. All participants will sign an informed consent which has been approved by the hospital ethical committee.

Interventions

PROCEDUREultra sound examination

Study design

Observational model

DEFINED_POPULATION

Time perspective

OTHER

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Inclusion criteria

* Pregnant women during the end of the pregnancy or immediately after birth (after 36 weeks)

Exclusion criteria

* Pregnant women before 36 weeks of pregnancy. * Known diabetes or treatment by drugs known to cause fatty liver.

Countries

Israel

Contacts

Primary ContactEfrat Broide, MD

efibroide@yahoo.com972-8-9779722

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026